Aldebaran Financial Inc. Has $490,000 Holdings in Eli Lilly and Company (LLY)
Aldebaran Financial Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 16.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,950 shares of the company’s stock after buying an additional 850 shares during the quarter. Aldebaran Financial Inc.’s holdings in Eli Lilly and were worth $490,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in LLY. ARGI Investment Services LLC acquired a new stake in shares of Eli Lilly and in the 1st quarter valued at $205,000. Alliancebernstein L.P. lifted its position in Eli Lilly and by 30.3% during the 1st quarter. Alliancebernstein L.P. now owns 3,477,371 shares of the company’s stock worth $292,482,000 after buying an additional 808,186 shares in the last quarter. Spark Investment Management LLC acquired a new position in Eli Lilly and during the 1st quarter worth about $1,749,000. Boston Private Wealth LLC lifted its position in Eli Lilly and by 7.8% during the 1st quarter. Boston Private Wealth LLC now owns 25,078 shares of the company’s stock worth $2,109,000 after buying an additional 1,805 shares in the last quarter. Finally, Investment House LLC lifted its position in Eli Lilly and by 4.4% during the 1st quarter. Investment House LLC now owns 32,247 shares of the company’s stock worth $2,712,000 after buying an additional 1,350 shares in the last quarter. 76.45% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company (NYSE LLY) traded up $0.68 during trading on Friday, reaching $85.32. 2,736,321 shares of the company’s stock were exchanged, compared to its average volume of 3,669,394. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 52 week low of $65.96 and a 52 week high of $89.09. The firm has a market cap of $93,950.00, a P/E ratio of 20.80, a PEG ratio of 1.87 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the prior year, the company posted $0.88 EPS. The company’s revenue was up 9.0% compared to the same quarter last year. research analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.44%. Eli Lilly and’s payout ratio is presently 99.05%.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 592,003 shares of company stock worth $50,246,641. Corporate insiders own 0.20% of the company’s stock.
LLY has been the topic of several research reports. Jefferies Group reiterated a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a research report on Monday, September 11th. BMO Capital Markets reiterated an “underperform” rating and set a $71.00 price target (down previously from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies reiterated an “overweight” rating and set a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Finally, Berenberg Bank reiterated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $90.25.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.